Ludwig-Maximilians-Universitaet Muenchen
Ludwig-Maximilians-Universitaet Muenchen is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia
Sponsor University Hospital Of Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and safety of Debio 4126, a 12-week octreotide formulation, in patients with acromegaly previously treated with somatostatin analogs.
Sponsor Debiopharm International S.A.
- Start (EU)
- Latest update
- Estimated end
PROTamine Application in patients underGOing tRAnScatheter aortic valve replacement (PROTAGORAS)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A single dose of apixaban for the prevention of thrombotic events in the context of long-distance flights (DANCE FLIGHT)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Clinical Trial on PREnatal Dexamethasone In Congenital adrenal hyperplasia Therapy - PREDICT -
Sponsor Philipps-Universitaet Marburg
- Start (EU)
- Latest update
- Estimated end
- Not reported
Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia - A MULTICENTER OPEN LABEL, SINGLE ARM EUROPEAN PHASE II STUDY (ECWM-2)
Sponsor University Hospital Of Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary syndrome undergoing percutaneoUS coronary intervention (EPIDAURUS)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1)
Sponsor Universitaetsklinikum Ulm AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Ludwig-Maximilians-Universitaet Muenchen?
The 2026-10-09 snapshot links Ludwig-Maximilians-Universitaet Muenchen to 8 distinct CTIS trials. Recorded services include Statistical analysis, Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ludwig-Maximilians-Universitaet Muenchen?
The most frequently recorded therapeutic areas are Cardiology, Endocrinology, Haematological Malignancies. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ludwig-Maximilians-Universitaet Muenchen conducted?
The linked trials record locations in 17 countries, including Germany, Austria, Greece, France, Belgium. These are trial locations, not confirmed office locations or countries where Ludwig-Maximilians-Universitaet Muenchen delivered services.
What can this page tell me about Ludwig-Maximilians-Universitaet Muenchen's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Ludwig-Maximilians-Universitaet Muenchen. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ludwig-Maximilians-Universitaet Muenchen